Here is the latest financial fact sheet of GSK PHARMA. For more details, see the GSK PHARMA quarterly results and GSK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 7.1 |
No. of shares | m | 169.41 |
1 Week | % | 9.5 |
1 Month | % | 8.1 |
1 Year | % | 65.9 |
52 week H/L | Rs | 2,650.0/1,228.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GSK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 3,595 | 1,745 | 1,805 | 1,917 | 1,684 | |
Low | Rs | 1,253 | 1,046 | 1,155 | 1,400 | 1,231 | |
Sales per share (Unadj.) | Rs | 184.6 | 190.3 | 172.7 | 193.5 | 191.9 | |
Earnings per share (Unadj.) | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 | |
Diluted earnings per share | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 | |
Cash flow per share (Unadj.) | Rs | 29.2 | 10.4 | 21.6 | 26.5 | 39.8 | |
Dividends per share (Unadj.) | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | |
Adj. dividends per share | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | |
Avg Dividend yield | % | 0.8 | 2.9 | 2.0 | 5.4 | 2.2 | |
Book value per share (Unadj.) | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 | |
Adj. book value per share | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 | |
Shares outstanding (eoy) | m | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 | |
Price / Sales ratio | x | 13.1 | 7.3 | 8.6 | 8.6 | 7.6 | |
Avg P/E ratio | x | 92.2 | 253.7 | 87.3 | 73.8 | 40.6 | |
P/CF ratio (eoy) | x | 83.1 | 134.4 | 68.5 | 62.6 | 36.7 | |
Price / Book Value ratio | x | 19.2 | 13.0 | 17.0 | 10.6 | 14.2 | |
Dividend payout | % | 76.1 | 727.0 | 176.9 | 400.4 | 89.2 | |
Avg Mkt Cap | Rs m | 410,644 | 236,440 | 250,695 | 280,960 | 246,858 | |
Total wages/salary | Rs m | 5,372 | 6,286 | 6,162 | 6,102 | 5,950 |
GSK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 31,281 | 32,244 | 29,256 | 32,780 | 32,517 | |
Other income | Rs m | 1,023 | 790 | 1,106 | 758 | 1,007 | |
Total revenues | Rs m | 32,304 | 33,034 | 30,362 | 33,538 | 33,524 | |
Gross profit | Rs m | 6,295 | 3,158 | 4,255 | 7,735 | 8,033 | |
Depreciation | Rs m | 486 | 827 | 786 | 682 | 658 | |
Interest | Rs m | 6 | 63 | 35 | 20 | 18 | |
Profit before tax | Rs m | 6,827 | 3,058 | 4,540 | 7,790 | 8,364 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,373 | 2,125 | 1,667 | 3,983 | 2,288 | |
Profit after tax | Rs m | 4,454 | 932 | 2,873 | 3,808 | 6,076 | |
Gross profit margin | % | 20.1 | 9.8 | 14.5 | 23.6 | 24.7 | |
Effective tax rate | % | 34.8 | 69.5 | 36.7 | 51.1 | 27.4 | |
Net profit margin | % | 14.2 | 2.9 | 9.8 | 11.6 | 18.7 |
GSK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 33,559 | 17,748 | 20,225 | 37,079 | 24,943 | |
Current liabilities | Rs m | 28,041 | 10,220 | 13,546 | 16,984 | 13,264 | |
Net working cap to sales | % | 17.6 | 23.3 | 22.8 | 61.3 | 35.9 | |
Current ratio | x | 1.2 | 1.7 | 1.5 | 2.2 | 1.9 | |
Inventory Days | Days | 351 | 42 | 51 | 91 | 97 | |
Debtors Days | Days | 141 | 113 | 269 | 229 | 216 | |
Net fixed assets | Rs m | 44,451 | 12,479 | 8,089 | 8,121 | 6,988 | |
Share capital | Rs m | 1,694 | 1,694 | 1,694 | 1,694 | 1,694 | |
"Free" reserves | Rs m | 19,704 | 16,512 | 13,089 | 24,936 | 15,735 | |
Net worth | Rs m | 21,398 | 18,206 | 14,783 | 26,630 | 17,430 | |
Long term debt | Rs m | 2 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 78,043 | 30,227 | 30,115 | 45,201 | 31,930 | |
Interest coverage | x | 1,233.3 | 49.3 | 129.6 | 391.3 | 462.6 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.4 | 1.1 | 1.0 | 0.7 | 1.0 | |
Return on assets | % | 5.7 | 3.3 | 9.7 | 8.5 | 19.1 | |
Return on equity | % | 20.8 | 5.1 | 19.4 | 14.3 | 34.9 | |
Return on capital | % | 31.9 | 17.1 | 31.0 | 29.3 | 48.1 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 22.7 | 27.1 | 39.0 | 27.0 | 48.1 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 | |
Fx inflow | Rs m | 534 | 276 | 278 | 528 | 1,622 | |
Fx outflow | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 | |
Net fx | Rs m | -6,557 | -8,474 | -11,119 | -8,325 | -14,008 |
GSK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 4,095 | 4,905 | 5,779 | 8,107 | 4,842 | |
From Investments | Rs m | -1,535 | -568 | 4,180 | -4,055 | 8,079 | |
From Financial Activity | Rs m | -3,584 | -4,276 | -6,956 | -5,242 | -15,433 | |
Net Cashflow | Rs m | -1,023 | 60 | 3,004 | -1,190 | -2,512 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: R S Karnad | COMP SEC: Ajay Nadkarni | YEAR OF INC: 1924 | BSE CODE: 500660 | FV (Rs): 10 | DIV YIELD (%): 1.5 |
Read: GSK PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GSK PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.